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Abstract: Levosimendan is an inodilator that promotes cardiac
contractility primarily through calcium sensitization of cardiac
troponin C and vasodilatation via opening of adenosine
triphosphate–sensitive potassium (KATP) channels in vascular
smooth muscle cells; the drug also exerts organ-protective effects
through a similar effect on mitochondrial KATP channels. This
pharmacological profile identifies levosimendan as a drug that
may have applications in a wide range of critical illness situations
encountered in intensive care unit medicine: hemodynamic sup-
port in cardiogenic or septic shock; weaning from mechanical
ventilation or from extracorporeal membrane oxygenation; and
in the context of cardiorenal syndrome. This review, authored
by experts from 9 European countries (Austria, Belgium, Czech
republic, Finland, France, Germany, Italy, Sweden, and Switzer-
land), examines the clinical and experimental data for levosimen-
dan in these situations and concludes that, in most instances, the
evidence is encouraging, which is not the case with other cardi-
oactive and vasoactive drugs routinely used in the intensive care
unit. The size of the available studies is, however, limited and the
data are in need of verification in larger controlled trials. Some
proposals are offered for the aims and designs of these additional
studies.
Key Words: inodilator, hemodynamic support, cardiogenic shock,
septic shock, weaning, mechanical ventilation, extracorporeal mem-
brane oxygenation, cardiorenal syndrome
(J Cardiovasc Pharmacol 2019;73:3–14)
THE CALCIUM SENSITIZER LEVOSIMENDAN
Levosimendan is a positive inotropic compound with
vasodilatory properties1 used for the treatment of acute de-
compensated heart failure (HF) and in cases where the use
of an inotropic treatment is considered appropriate.2 The
principal mechanism of levosimendan is the sensitization
of troponin C to calcium in cardiac muscle,3–5 which leads
to its unique feature of exerting a positive inotropic effect
without increasing myocardial oxygen consumption.6–10
In addition, levosimendan opens adenosine triphosphate–
sensitive potassium (KATP) channels in vascular smooth
muscle cells11,12 and induces vasodilation of the pulmo-
nary,13 coronary,14,15 and peripheral arteries16 and of the
venous circulation.17 By addressing both cardiac inotropy
and vascular dilatation, levosimendan improves cardiovas-
cular coupling and cardiac mechanical efficiency. Levosi-
mendan also opens mitochondrial KATP channels18 and
exerts an organ-protective and, especially, cardioprotective
effect in various settings.19,20 At higher doses, the drug also
acts as a phosphodiesterase type 3 (PDE3) inhibitor.1,12,21,22
The effects of levosimendan are not impaired by the con-
comitant use of beta-blockers.23
Levosimendan has been studied in several therapeutic
applications, particularly in the management of acute HF
(AHF) patients with low cardiac output24,25 and in high-
risk cardiac surgery.26,27 Levosimendan has also shown
preliminary positive effects in a range of other conditions
requiring inotropic support, including right ventricular fail-
ure, cardiogenic shock (CS), septic shock, and Takotsubo
cardiomyopathy.28
Owing to its pharmacology, it has become apparent that
levosimendan may also have applications in the setting of
intensive care medicine. The conceptual framework for this
wider use of levosimendan has been set out by Farmakis
et al28 and is supported by an array of experimental and
observational research29–37 (Box 1).
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BOX 1.
Expected Effects of Levosimendan in Intensive
Care Unit Settings
• General hemodynamic support;
• Increased ejection fraction and cardiac index without
increase of oxygen consumption;
• Peripheral vasodilation and reduction of tissues and
organ hypoperfusion;
• Increased GFR and renal function;
• Decrease in need for catecholamines;
• Sustained effects; and
• No increase in long-term mortality.
This commentary identifies a range of clinical situations
encountered in the intensive care unit (ICU) where levosi-
mendan may offer clinical advantages, either as an adjunct to
standard-of-care therapies or as an alternative to conventional
therapies (Box 2).
HEMODYNAMIC SUPPORT IN CARDIAC
CRITICAL CARE
In severe AHF and CS, congestion and hypoperfusion
lead to a systemic disorder that potentially affects all vital
organs. Restoring adequate cardiac output and organ perfu-
sion, and promoting decongestion, are therefore medical
priorities during the early phase of treatment.38–40
In AHF leading to tissue hypoperfusion, initial use of
an inotrope is advocated.40,41Hence, inotropic support re-
mains a cornerstone of AHF management in these critically
ill patients, together with adequate fluid resuscitation (or
depletion) and optimization of arterial pressure to suit the
individual features of patients.
Reported rates of inotropic support in AHF man-
agement vary from 9% in an early US registry42 to .30%
in a later international registry43 and 13% in the 2017
European Society of Cardiology (ESC) Heart Failure
Long-Term Registry.44 Robust secular trends in the use
of inotropes are hard to identify from these fluctuations
but dobutamine remains the most frequently used
inotrope.
BOX 2.
Intensive Care Unit Settings in Which the Use
of Levosimendan Has Been Described
• Cardiogenic shock;
• Septic shock;
• Weaning from ventilator;
• Weaning from extracorporeal membrane oxygenation;
• Pulmonary hypertension and right ventricular dysfunc-
tion; and
• Need for hemodynamic support in patients with diuretic
resistance.
The indication for inotropic support depends largely on
the etiology; heading this hierarchy is CS, for which, by
definition, virtually all patients are supported by at least one
inotropic drug.45 In septic shock, inotropic support is de-
ployed according to current precepts of early goal-directed
therapy (EGDT); in recent EGDT trials, rates of inotrope
use ranged fromz15% for patients included in the interven-
tion groups to usually ,5% for those in the standard-of-care
groups.46 The prevalence of inotropic support at admission
was 15%–20% in a recent pragmatic multicenter trial of lev-
osimendan in septic shock.37 Inotropic support may also be
considered in cases of obstructive shock, while waiting for the
obstruction to be removed, but continuation after that point
would be uncommon.
Dobutamine is the first-line inotropic agent for resus-
citating patients suffering from either severe AHF and low-
cardiac output syndrome40 in CS41,47 or septic shock48 but its
administration entails substantial addition of exogenous cat-
echolamines to the endogenous ones already overproduced by
the intense activation of the sympathetic autonomous nervous
system.
The resulting exacerbation of the beta-adrenergic
pathway induces an increase in myocardial oxygen con-
sumption via chronotropic and inotropic effects.49 This
catecholamine-induced myocardial oxygenation imbalance
exacerbates myocardial ischemia,50,51 especially at the
level of the subendocardium.52 Inter alia, excessive adren-
ergic stimulation is also established as a key factor in the
pathophysiology of Takotsubo cardiomyopathy53 and con-
tributes substantially to some manifestations of the septic
cardiomyopathies.54
Various large international registries relating to AHF
and CS have documented higher rates of morbidity and
mortality in patients treated with adrenergic inotropes than
in severity-matched peers who did not receive catechol-
amines42–45; a recent meta-analysis of randomized clinical
trials of dobutamine to treat severe (acute or chronic) HF
likewise indicated an increased risk of mortality.55 These
observations, with others,56 are the basis of the European
Society of Intensive Care Medicine AHF/CS guidance that
“The use of these [inotropic/vasopressor] agents should,
however, be restricted to the shortest possible duration and
lowest possible dose to maintain perfusion pressure”57 and
the declaration in the ESC HF guidelines that “There is long-
standing concern that [inotropes, especially those with
adrenergic mechanisms] may increase mortality.”40
In a randomized clinical trial involving patients with
acutely exacerbated chronic HF, the PDE3 inhibitor
milrinone was shown to increase mortality in patients
suffering from ischemic cardiomyopathy58: a similar find-
ing was also reported in a recent large retrospective cohort
study of intraoperative inotropic support in cardiac sur-
gery.59 These data indicate that milrinone (and, by exten-
sion, other PDE3 inhibitors) is not a fully satisfactory
alternative to dobutamine. Similar reservations apply to
dopamine44,60 and epinephrine.45,61
The “decatecholaminization” of the critically ill patient
represents a new and still-evolving paradigm in the treatment
of patients in the ICU.62,63 One avenue for research in this
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area has been the evaluation of nonadrenergic vasoactive
agents.64–66 These include levosimendan, which offers posi-
tive cardiovascular effects (ventriculoarterial recoupling,
decongestion, and cardiac protection against ischemia–
reperfusion injury) as well as potentially advantageous
ancillary effects on kidney function and diaphragm muscular
fibers, as discussed later in this review.
LEVOSIMENDAN IN CARDIOGENIC SHOCK
Acute myocardial infarction (AMI) is the most common
etiology of CS but CS may arise from any situation of acute,
severe dysfunction in either ventricle of the heart. CS is
relatively rare but often fatal.67
The standard of care in CS consists of primary percuta-
neous coronary intervention for AMI, fluid therapy, vasopressors,
inotropes and, in the last resort, mechanical assistance.68 Data
from initial comparator studies indicate that levosimendan may
be a useful addition to this regimen.
Levosimendan may be a constructive alternative to
conventional inotropes for the management of CS. In a trial of
22 consecutive AMI patients who developed CS after
percutaneous coronary intervention, levosimendan (24 mg/kg
bolus, then 0.1 mg/kg/min for 24 hours) attained the study end
point of $30% increase in cardiac power output (CPO) con-
sistently better than dobutamine (initial dose 5 mg/kg/min,
with subsequent dose increases to reach the desired hemody-
namic effect), despite a comparable reduction in pulmonary
capillary wedge pressure69 (Fig. 1) (CPO is the product of
cardiac output and mean arterial pressure [MAP] and an indi-
cator of cardiac contractility and ventricular–vascular cou-
pling: in effect, it represents the pumping power of the heart
and has been identified as the strongest predictor of survival
in patients with CS70).
Levosimendan also compared favorably with the PDE
inhibitor enoximone in an exploratory open-label study of CS
secondary to AMI, giving a small but significant advantage in
death from multiorgan failure (Pz 0.02).71 Beneficial hemo-
dynamic effects were recorded in both groups, including
enhancement of CPO, but these changes were achieved
sooner with levosimendan than with enoximone. There was
a significant advantage with levosimendan in terms of fewer
deaths from multiorgan failure (P , 0.05). Use of dobut-
amine and norepinephrine in the levosimendan-treated pa-
tients was much lower than that in the enoximone group. It
is plausible that part of the survival advantage seen with
levosimendan may be attributable to a reduction in exposure
to exogenous catecholamines.
Notwithstanding these data, levosimendan is currently
regarded as a salvage therapy in CS after dobutamine failure
and before extracorporeal life support (ECLS). Any revision
of this status will require well-designed randomized con-
trolled studies.72 Until then, the use of levosimendan may be
considered in cases of low cardiac output associated with
signs of hypoperfusion or deteriorating renal/liver function,
especially if beta-blocker use is part of the clinical scenario.
Use of levosimendan is contraindicated in hypovole-
mia, which must be excluded using echocardiography and/or
advanced monitoring and dynamic indices. Cardiac output
monitoring (transpulmonary thermodilution or pulmonary
artery catheterization in cases of associated right ventricular
dysfunction) is highly recommended.
Omitting a loading dose seems a rationale choice,
while the maintenance infusion for a total duration of
24 hours (0.05–0.2 mg/kg/min) should be individually
adjusted. After levosimendan is started, dobutamine may
be weaned according to the hemodynamic and clinical
response (generally after 2 hours). As soon as possible,
but after weaning of vasopressors, established chronic
HF treatments should be (re-)introduced.
In practice, systolic dysfunction and diastolic dysfunc-
tion often coexist. The management of circulatory failure
related to diastolic dysfunction in critical illness is largely
supportive. Adequate fluid resuscitation is often followed by
the administration of drugs with a positive lusitropic effect.
Levosimendan has been shown to improve diastolic func-
tion73 and filling and, importantly, it can be safely combined
with beta-blockers, which represent one of the potential treat-
ment modalities for diastolic dysfunction.
LEVOSIMENDAN IN SEPTIC SHOCK
Sepsis is defined nowadays as an infection inducing
dysfunction of at least one organ owing to a deregulated host
inflammatory response.74 In addition to intrinsic distributive
shock due to vascular hyporeactivity and autonomic dysfunc-
tion, sepsis can also induce septic cardiomyopathy (SCM)
with de novo AHF due to myocardial depression. Such com-
plications contribute to a sepsis mortality rate of z30%.74,75
The prevalence of SCM among septic patients varies widely
(from 20% to 60%), a state of affairs that reflects both the
current lack of a common definition and the heterogeneity of
the symptoms.75
Inotropic support is endorsed for restoration of an
adequate cardiac output and peripheral oxygen delivery.48 In
FIGURE 1. Changes in CPO during infusion of levosi-
mendan ( ) and dobutamine ( ) in patients with AMI re-
vascularized by percutaneous coronary intervention and
who developed cardiac shock. Data points are mean 6 SD.
*P , 0.05 (Student’s t-test). Data from the study by Garcı´a-
Gonza´lez et al.69
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the absence of a fully evidence-based alternative, dobutamine
remains the suggested first-line inotrope for those goals,
despite the observations that: (1) high levels of circulating
catecholamines and adrenergic overstimulation contribute to
the pathophysiology of SCM54,76; (2) the adrenergic response
at the cardiomyocyte level is attenuated by downregulation of
b-adrenergic receptors77,78; (3) adrenergic drugs have been
associated with worse outcomes in a pooled network meta-
analysis36; and (4) esmolol, a b1-receptor antagonist, seems to
improve the outcome of severe SCM,78 especially in cases of
persistent tachycardia.79
Proceeding from the above points, assessment of
levosimendan as an alternative inotropic drug in septic
shock should address the following clinical goals and
criteria.
1. Dobutamine sparing: reducing the high (toxic) levels of
endogenous and pharmacological adrenergic stimulation
and hence restoring a better myocardial oxygenation bal-
ance, particularly in the case of coronary artery disease
with potential catecholamine-induced ischemia.51
2. Attenuation of multiple-organ failure (MOF): reducing the
occurrence and/or severity of sepsis-induced MOF due to
better regional blood flow distribution in addition to
a global increase in cardiac output, plus pleiotropic effects
at the cellular and mitochondrial levels.28,80
3. Inotropic rescue therapy: restoring inotropic responsive-
ness in cases of severely attenuated adrenergic response.
4. Drug safety: replacing adrenergic inotropic drugs with-
out tachyarrhythmia or any additional requirement for
vasopressors.
Experimental studies (mainly in animal models of
peritonitis-induced septic shock) have demonstrated an
improvement in survival, and a reduction in the severity of
MOF and anti-inflammatory protective effects with levosi-
mendan.80,81 It must be acknowledged, however, that many of
those studies were restricted to comparison versus placebo,
not other inotropes.
As regards clinical trials of levosimendan in septic
shock, in a monocentric randomized controlled trial, a 24-hour
infusion of levosimendan (0.2 mg/kg/min) was compared with
dobutamine (5 mg/kg/min) as inotropic support for patients
with de novo severe SCM (n = 28) and a left ventricular
ejection fraction (LVEF) ,45% despite 48 hours of conven-
tional standard-of-care treatment, including dobutamine.82 Lev-
osimendan use was associated with increases in cardiac output
and pulmonary decongestion, without an increase in vasopres-
sor requirements (owing to volume expansion) and with more
favorable evolution of various MOF surrogates (lactate clear-
ance, venoarterial carbon dioxide gap, gut mucosal perfusion,
and renal function). Dobutamine did not materially alter any of
these systemic or regional hemodynamic variables.
The findings of this study satisfy the clinical goals
identified above and are, to that extent, promising regarding
the potential of levosimendan in sepsis and SCM. However,
this was a single study with several limitations and must be
considered indicative, not definitive.83
The biological mechanisms underpinning this attenua-
tion of MOF have been explored in subsequent clinical trials:
levosimendan infusion has been shown to improve microcir-
culation perfusion,84 relieve mitochondrial oxidative stress,85
and restore the muscular lactate/pyruvate ratio.86 Some of this
research, plus additional small clinical trials of heterogeneous
quality, has been incorporated into a meta-analysis87 of the
effects of levosimendan in septic shock versus standard ino-
tropes (invariably dobutamine where specified). Findings
from this exercise (7 studies, 249 patients) included a signif-
icant reduction in mortality in the levosimendan group with-
out intergroup differences in MAP or norepinephrine usage.
These clinical observations, together with a strong
experimental background, led to the development of a large
pragmatic multicenter randomized placebo-controlled trial of
levosimendan in sepsis. This study—Levosimendan for the
Prevention of Acute oRgan Dysfunction in Sepsis (LeoP-
ARDS; ISRCTN12776039)—examined whether early admin-
istration of levosimendan (0.05–0.2 mg/kg/min for 24 hours)
could avert the onset of MOF in a broad population of septic
shock patients (n = 516) fulfilling the criteria for systemic
inflammatory response syndrome due to infection and requir-
ing vasopressor therapy for at least 4 hours.37
LeoPARDS did not fulfill the primary end point of
a significant intergroup difference in mean daily Sequential
Organ Failure Assessment score favoring levosimendan, and
nor was mortality reduced. Although prima facie disappoint-
ing, these findings should be considered in perspective. This
was a relatively low-risk cohort; most patients were not
suffering from either severe circulatory shock or severe SCM
needing inotropic support. Moreover, the degree of renal
replacement therapy already being undertaken before ran-
domization was substantial and may have led to faster
elimination of the study drug in 17% of patients in the
intervention group. These reasons may have resulted in
LeoPARDS lacking the necessary focus to identify an effect
of levosimendan on the patients who could have benefitted.
The currently available clinical evidence in septic shock
indicates that: (1) Levosimendan can successfully replace
dobutamine in supporting severe de novo AHF due to SCM,
with additional positive extracardiac effects owing to ame-
lioration of MOF. These results need to be replicated on
a larger scale; and (2) Indiscriminate use of levosimendan (ie,
without selecting severe cases of cardiovascular failure) to
prevent the development of MOF is safe from a hemodynamic
perspective but may confer no clinical benefit.
In addition, however, recent data from patients in septic
shock show ventriculoarterial uncoupling due to either
ventricular elastance reduction (as in SCM) or increased
arterial elastance due to vasopressor therapy, or both: this is
a situation in which cardiac mitochondrial function can be
severely impaired and the oxygen metabolism altered.88 No
data are currently published on the effect of levosimendan on
ventriculoarterial coupling in septic shock, but this matter
merits research because the mechanism of action of levosi-
mendan may contribute to the restoration of more normal
coupling.
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Future investigations to refine the role of levosimendan
in the management of septic shock should address (1) the
severity of AHF (a priori, there is a case for reserving
levosimendan for patients more likely to benefit from it, such
as those with severely reduced LVEF or significant coronary
artery disease26,89); and (2) the timing of the administration
(under which heading, matters for attention include investi-
gation of levosimendan as a first-use inotrope for severe SCM
to optimize its positive cardioprotective effects as intimated
from various lines of research, including randomized trials in
cardiac surgery that recorded better outcomes with earlier
administration89–92).
LEVOSIMENDAN AND WEANING FROM
THE VENTILATOR
About 10%–20% of intubated patients in ICUs are diffi-
cult to wean from mechanical ventilation, resulting in increased
morbidity, mortality, and health care costs.93,94 Part of this
phenomenon may be attributable to the development of dia-
phragm weakness in intubated patients. Mechanical ventilation
results in rapid loss of diaphragmatic force production.95–97 In
one recent study, half of the patients (n = 185) with diaphrag-
matic dysfunction failed weaning, half of whom died.98 In
addition, liberation from mechanical ventilation to spontaneous
ventilation may dramatically increase left ventricular filling
pressure and pulmonary artery pressure, especially in patients
with preexisting cardiac and/or pulmonary comorbidities.
The pathophysiology of muscle weakness in these
patients is complex99,100 but includes muscle fiber atrophy and
reduced calcium sensitivity of the contractile proteins.101
Because respiratory muscle troponin resembles cardiac troponin,
it is plausible that levosimendan may enhance muscular contrac-
tility in the same way that it enhances cardiac contractility. This
supposition has support from in vitro data,102 experimental
research,103 and a healthy volunteer study.104 Positive effects
were seen in both slow and rapid diaphragm muscle fibers.102,103
Levosimendan has been compared with dobutamine in
difficult-to-wean chronic obstructive pulmonary disease pa-
tients.105 Levosimendan resulted in significantly greater inhibi-
tion of spontaneous ventilation-induced congestion caused by
a rapid increase in pulmonary artery occlusion pressure. Simi-
larly, mean pulmonary artery pressure increased to a lesser
extent with levosimendan than with dobutamine. In a prospective
observational study in ventilator-dependent difficult-to-wean
ICU patients with diminished LVEF (,40%), levosimendan
improved cardiac contractility and oxygenation variables and
increased the likelihood of separation from mechanical ventila-
tion.93 A study entitled “Effects of Levosimendan on Dia-
phragm Function in Mechanically Ventilated Patients”
(NCT01721434) coordinated by the University Medical Center,
Nijmegen, the Netherlands, is currently recruiting.
LEVOSIMENDAN AND WEANING FROM
EXTRACORPOREAL MEMBRANE OXYGENATION
Venoarterial extracorporeal membrane oxygenation
(VA-ECMO) is increasingly used for short-term management
of refractory CS caused by AMI, myocarditis, cardiac surgical
procedures in high-risk patients with reduced LVEF, refrac-
tory cardiac arrest, and other conditions. In general, it is
reserved for situations where pharmacological support of the
circulation is not able to restore adequate cardiac output. In
cases where there is sufficient recovery of myocardial
function during VA-ECMO support, the phase of weaning
starts by reducing blood flow through VA-ECMO and thus
increasing blood flow to the native heart chambers and
pulmonary circulation, ie, increasing the load imposed on
both ventricles. In a large observational study, the rate of
successful weaning in 4658 patients with CS was reported to
be limited to 65.7%.106
A first report on levosimendan in the context of VA-
ECMO weaning showed that pretreatment 24 hours before the
start of weaning was associated with a 50% reduction in the
need for inotropic and/or vasopressor support during or after
weaning, compared with a 100% requirement in the retrospec-
tive control group (n = 11) (P, 0.003).107 The weaning success
rate was significantly higher with levosimendan (83.3% vs.
27.3%; P = 0.0498); the difference in survival rate was sub-
stantial but not statistically significant (66.6% vs. 36.4%).
In a recent retrospective analysis of 240 patients on VA-
ECMO after cardiovascular surgery, levosimendan was given
during the first 24 hours of ECMO support in 74.6% of cases.108
The adjusted hazard ratio for failure of ECMO weaning with
levosimendan was significantly improved versus control (hazard
ratio 0.41; 95% confidence interval 0.22–0.80; P = 0.008);
furthermore, patients in the levosimendan group experienced
lower 30-day mortality (P = 0.016) and better long-term survival
(Fig. 2). Another study reported improvement in endothelial func-
tion after levosimendan infusion in the patients on VA-ECMO,
together with an improvement in cardiac function (ie, an increase
in cardiac output), facilitating weaning from ECMO.109 Very
recent data show that levosimendan enables weaning from ECLS
without increasing norepinephrine requirements when compared
with a control group receiving milrinone.110
Most patients require inotropic drugs to support myo-
cardial contractile function during weaning from VA-ECMO,
and the limited clinical evidence currently available suggests
that levosimendan offers some important advantages over other
inotropes for this vulnerable period: no increase in myocardial
oxygen consumption, a prolonged cardiovascular effect (days),
and improvement in endothelial function.
LEVOSIMENDAN IN PULMONARY HYPERTEN-
SION AND RIGHT VENTRICULAR DYSFUNCTION
Acute postoperative pulmonary hypertension is a rare but
serious event after weaning from cardiopulmonary bypass and
must be managed aggressively to avoid right ventricular
failure.111,112 The in-hospital mortality rate is high and may
reach 70%–75%.113,114 Similar considerations apply in non-
surgical ICUs where right ventricular dysfunction may emerge
as a complication of acute respiratory distress syndrome.115
The thin-walled right ventricle has poor tolerance for
acute increases in afterload. Ventricular distension leads to
severe compromise of contractility concomitant with an
increase in oxygen consumption. Ventricular interdependence
then implicates the left ventricle, leading to reduced filling,
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decreased cardiac output and oxygen delivery, and decline in
systemic perfusion pressure.116 The pressure gradient for the
perfusion of the right coronary artery drops as aortic pressure
decreases and right ventricular pressure increases, leading to
right ventricular ischemia.117
Augmentation of right ventricular function with inotropic
support is central to counteracting this vicious cycle. Levosi-
mendan improves myocardial contractility, with a reduction in
pulmonary vascular resistance.118 In an experimental pressure
load–induced model of right ventricular failure, levosimendan
improved right ventricular to pulmonary artery coupling more
than dobutamine.119 The treatment of acute right ventricular
failure involves reversing the cause of the increased pulmonary
vascular resistance while maintaining adequate MAP. To
support adequate systemic arterial tone, a vasopressor is often
required, while levosimendan helps to decrease pulmonary
vascular resistance and filling pressures.
Investigator-initiated studies have been performed in
patients with right ventricular failure. In these, levosimendan
reduced increased right ventricular afterload and improved
right ventricular contractility and diastolic function.120–123
A recent meta-analysis demonstrated that levosimendan
decreased systolic pulmonary pressure and pulmonary vascular
resistance concomitant with an increase in right ventricular
ejection fraction in patients suffering from acute right HF.124
Much of the extant data come from noncardiac surgery patients
suffering from the acute onset of pulmonary hypertension and/
or right ventricular dysfunction; data on levosimendan in acute
right ventricular failure are sparse though encouraging.125
LEVOSIMENDAN AND RENAL FUNCTION
Evidence for a renal-protective action of levosimendan
in preclinical experiments is persuasive but the clinical data
set supporting a renal-protective effect rests on a limited number
of studies, many of which are small and characterized by
heterogeneities.126 The results of those studies acquire signifi-
cance only when pooled in meta-analyses127–130 but, addressed
in that way, the findings are suggestive of a renal-protective
effect of levosimendan in a range of cardiac low-output states
that may be pertinent to the ICU setting.
Levosimendan has been compared with dobutamine in
88 patients with HF who required inotropic therapy.131 Calcu-
lated glomerular filtration rate (GFR) improved in response to
levosimendan (0.1–0.2 mg/kg/min, with loading dose at the
discretion of individual physicians) but was unchanged in pa-
tients who received dobutamine (5 mg/kg/min for at least 6
hours, with subsequent dose alteration or extension beyond
24 hours as judged necessary in individual cases). Complemen-
tary findings emerged from a placebo-controlled study in 66
patients hospitalized for decompensated HF and renal dysfunc-
tion, with a statistically significant improvement in calculated
GFR in patients who received levosimendan (12 mg/kg
optional loading dose, then continuous infusion at 0.05–0.2
mg/kg/min for 24 hours). Peak effect was attained 3 days after
a 24-hour infusion and the effects persisted for up to 14
days.132 Two open-label studies also reported reduction of
serum creatinine levels in levosimendan-treated patients.133,134
In a recent randomized study135 on the effect of levosimendan
on renal outcome in 90 cardiac surgery patients with chronic
kidney disease and perioperative cardiovascular dysfunction,
the authors reported a significant reduction in postoperative
acute kidney injury (AKI) and a lower incidence of major
complications in the levosimendan arm.
What are the mechanisms behind the clinical observa-
tion that levosimendan seems to improve renal function in
patients with AHF requiring inotropic support? Inodilators
increase cardiac output and also potentially renal blood flow
(RBF). It is not immediately evident, however, that an
inodilator with renal vasodilating properties also increases
GFR: it depends on its effect on the longitudinal distribution
of renal vascular resistance. Thus, theoretically, an inodilator
that dilates the preglomerular resistance vessels (afferent
arterioles) will, at a certain MAP, increase both RBF and
GFR. However, an inodilator that preferentially causes
vasodilation of the postglomerular resistance vessels (efferent
arterioles) will increase RBF but cause a fall in GFR, due to
a fall in the upstream glomerular hydraulic pressure. Finally,
an inodilator that dilates both preglomerular and postglomer-
ular resistance vessels will induce a pronounced increase in
RBF with no change in GFR. Redfors et al136 showed in
postcardiac surgery patients that low-dose dopamine (2–4
mg/kg/min) induced a pronounced 40%–50% increase in
RBF with no effect on GFR, suggesting vasodilation of both
preglomerular and postglomerular resistance vessels. Levosi-
mendan, however, has been shown to increase both RBF and
GFR after cardiac surgery, indicating that, in contrast to dopa-
mine, levosimendan improves renal performance by means of
preferential preglomerular vasodilation137 (Fig. 3). The major
goal in the treatment of AKI is to increase GFR. There is,
however, a close association between GFR and renal oxygen
consumption138 because any agent that increases GFR will
also increase renal oxygen demand. Thus, an ideal inodilator
FIGURE 2. Confounder-adjusted long-term survival (levosi-
mendan vs. control, P = 0.04) in 240 patients weaned from
extracorporeal membrane oxygenation. Levosimendan was
administered within the first 24 hours after initiation of ECMO
therapy, at a standard dose of 12.5 mg in 24 hours. Data from
the study by Distelmaier et al.108
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to treat AKI would be one that increases both RBF and GFR.
Such an agent will not only increase GFR but will also meet the
increased renal metabolic demand by means of increased renal
oxygen delivery. Bragadottir et al137 showed that the
levosimendan-induced increase in GFR did not impair the renal
oxygen supply/demand relationship, suggesting that levosimen-
dan could be an interesting agent for treatment of AHF accom-
panied by impaired renal function in various clinical settings. In
a recent double-blind randomized clinical trial, the same group
recently showed that in patients with chronic HF and renal
impairment, levosimendan increases GFR to a greater extent
than dobutamine and thus may be the preferred inotropic agent
for treating patients with cardiorenal syndrome.139
Complementary findings were reported from a placebo-
controlled study by Fedele et al140 in patients with acute decom-
pensated HF and moderate renal impairment (NCT00527059).
Yilmaz et al126 have speculated on the likely contribution of
KATP channel-opening effects of levosimendan in vascular
smooth muscle to a direct renal-protective effect of levosimendan
separate from, and additional to, its effects through improved
cardiac function and systemic hemodynamics. Observations on
the significance of levosimendan-mediated vasodilatation and
decongestion have been made by Damman and Voors.141
Diuretic resistance in HF patients is a common prob-
lem. One treatment option could be the administration of
levosimendan. This might be a good option before the more
aggressive implementation of ultrafiltration.142
OTHER SETTINGS
Is to be noticed that the HFA-ESC Task Force on
Takotsubo syndrome143 advocates levosimendan as the single
form of inotropic support in cases of unavailable ECLS. Case
reports are encouraging,144 and the pathophysiology is con-
ceptually a good fit to the properties of levosimendan.
CONCLUSIONS
Levosimendan has been demonstrated to have potential
utility in a range of critical illness scenarios. It must be
acknowledged, however, that in each sphere of application,
the evidence is incomplete or indicative rather than conclu-
sive, and further clinical evaluation will be needed to
substantiate the case for levosimendan and to refine the
patient categories and dosage schedules likely to be associ-
ated with the greatest clinical benefit.
Having levosimendan a vasodilatory effect, its dos-
age should be guided in part by following the blood
pressure of the patient (as recommended by the indication
for use), with bolus omitted or used only if SBP is $100
mm Hg145 (Box 3). Meta-analysis of 45 randomized con-
trolled trials in cardiac surgery or cardiology identifies an
infusion rate range of 0.05–0.2 mg$kg21$min21, with some
indications that both lower rates (#0.1 mg$kg21$min21)
and omission of bolus dose may confer greater long-term
survival advantages over higher doses and use of bolus.146
The presence of a long-lived metabolite is associated with
the persistence of the hemodynamic effects of levosimen-
dan147 for 7–10 days after a single 24-hour infusion of
levosimendan. The inodilator levosimendan is mainly used
for its hemodynamic effects, and the longer action of its
active metabolite is fully consistent with the pharmacologic
effects observed in the beginning of the treatment: no
increase in the rate of adverse events was observed after
the 24-hour infusion of levosimendan.148
BOX 3.
Recommended Dosage of Levosimendan
When Used in Intensive Care Unit Settings
• Levosimendan dosage should be guided by following
the blood pressure;
• Bolus should be omitted or used only if SBP is $100
mm Hg;
• An infusion rate range of 0.05–0.2 mg$kg21$min21 starting
at 0.1 mg$kg21$min21 and uptitrated or downtitrated to the
doses, which gives hemodynamic stability while avoiding
adverse effects such hypotension and/or arrhythmias;
• Hypovolemia and hypokalemia should be avoided
before and during treatment;
• The presence of a long-lived metabolite is associated with
the persistence of the hemodynamic effects of levosimendan
7–10 days after a single 24-hour infusion of levosimendan;
• Levosimendan is mainly used for its hemodynamic ef-
fects, and the longer action of its active metabolite is
fully consistent with the pharmacologic effects observed
in the beginning of the treatment: no increase in the rate
of adverse events (hypotension and/or arrhythmia) is
observed after the 24-hour infusion of levosimendan.
FIGURE 3. Differential effects of levosimendan (0.1 mg/kg/min)
and dopamine (2 mg/kg/min) on RBF and GFR in 30 post-
cardiac surgery patients. The experimental procedure started
4–6 hours after surgery in the ICU during propofol sedation
and mechanical ventilation. Cardiac index (CI) was increased
by z20% by both drugs. Data from the study by Bragadottir
et al.137
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The regulatory Phase IIb–III clinical trials program on
the efficacy and safety of levosimendan in AHF completed in
2005 (see complete trial list in the study by Pollesello et al149)
did not give an unequivocal answer to the question whether
the short-term use of levosimendan lowers long-term mortal-
ity in patients hospitalized for decompensated AHF irrespec-
tively to its etiology and to the use of comedications during
the preacute, periacute, and postacute phase. Some trials
showed a significant improvement in survival, whereas some
(the larger ones) did not, but the bulk of evidence did overall
support the efficacy and safety of the drug, and a market
authorization was granted in over 60 countries, with the nota-
ble exception of the United States and the United Kingdom.
The regulatory studies included a broad variety of patients,
both as it regards the etiologies of AHF (eg, de novo vs.
chronic decompensated), the monitoring (eg, invasively vs.
non-invasively), the time of treatment (eg, early during hos-
pitalization vs. late), and the co-medications (eg, beta-
blockade vs. non–beta-blockade). When more homogeneous
groups of patients are considered (see the analysis by Kivikko
et al91), the short-term effects of levosimendan on symptoms,
hemodynamics, and neurohormones are accompanied to a sig-
nificant long-term effect on survival. As it regards the clinical
studies in the ICU field, the same pattern can be seen when
comparing the large LeoPARDS study37 with the many pre-
vious smaller studies on the use of levosimendan in septic
shock150: when the patients are poorly defined, the results are
so spread that not any statistical significance can be reached.
Therefrom originates the conundrum: in the field of ICU, the
large studies needed for “evidence-based medicine” necessar-
ily include a broad spectrum of patients and the effects of
drugs can be easily masked in the statistical analyses, whereas
smaller (often monocentric) studies can spot significant pos-
itive drug effects due to the more homogeneous selection of
patients, but their results will remain necessarily limited. We
hereby propose possible solutions for a way out.
Central to future investigations must be the identifica-
tion of robust and relevant end points. An improvement in
survival/mortality may be plausible in cases where levosi-
mendan substitutes for an adrenergic inotrope with a docu-
mented propensity to increase mortality. In other settings,
however, it is not obvious that a mortality gain can be
assumed nor is it certain that any such gain, welcome as it
would be, would be the most pertinent measurement of any
treatment effect. It is, moreover, unclear how far into the
future any survival benefit from a short-term intervention in
what is likely to be a complex and multifaceted medical crisis
should reasonably be expected to extend. None of the
conventional adrenergic inotropic drugs have in fact been
associated with improvements in hard end points such as
mortality, and there are many indications to the contrary. The
reported experience of Distelmaier et al108 (Fig. 2) is encour-
aging regarding the prospect of a long-term advantage in the
sphere of weaning from ECMO but may not be similarly
applicable in other situations and is in any case in need of
corroboration.
We consider, for these reasons, that an overemphasis on
crude mortality may not be the most informative approach to
future clinical trials of levosimendan. We are inclined toward
the position of Schumann et al,72 who have advocated the
evaluation of EGDT in CS and low-cardiac output syndrome,
arguing that refining the best therapeutic strategy is more
constructive than trying to identify the “best” drug for hemo-
dynamic support. Similarly, identifying the most effective
regimen for, say, weaning from ECMO or the management
of pulmonary hypertension needs to take a wider view of the
issue than simply focusing too closely on the impact of a sin-
gle intervention, perhaps delivered for a short period. The
adoption of hierarchical end points in clinical trials of levo-
simendan in HF (eg, LEODOR; NCT03437226)151 is an
innovation that may also find applications in future clinical
trials in the ICU setting and may enable a more nuanced
appraisal of the impact of levosimendan in those situations.
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